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1-2 minutes of clinicians time. The output obtains a
complex radiobiologic report and a graphical picture
with a "Terapeutic Ratio" for a relevant protocol.
Results
Comparison of rivals protocols for Ca of Uterine
Cervix liB, III (2 LDR insertions/20 Gy + EBRT
40,8 Gy versus 4 HDR insertions + EBRT 40.8
Gy) follows to an isoeffective HDR dose/fr =
6.65 Gy. Critical % doses (related to NTCP
rectum, bladder -5%) are 65% and 80% respectively.
It correlates with a maximum "Benefit function"
defined as BF-TCP (1-NTCP).
Conclusion
The contribution shows a simple and potentially
useful approach for computing more realistic
isoeffect relations for tumour, early and late
responding tissues when comparing different
radiotherapeutic protocols. It offers a real
chance to optimize a "Therapeutic gain" as a
final goal of radiation therapy.
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Adjuvant postoperative radiotherapy
combined with chemotherapy is considered a
standard management of rectal cancer patients
with increased risk of local recurrence. In this
study we evaluated the results of adjuvant
chemo- and radiotherapy after radical surgery in
64 patients with rectal carcinoma with special
reference to tolerance of treatment. All patients
underwent radical surgery: anterior abdominal
resection in 26, abdominoperineal resection in 19
and Hartman resection in one. Thirty three
patients were postoperatively staged as Dukes
82 and 31 patients - as Dukes C. All patients
received postoperative chemo-radiotherapy.
Treatment included megavoltage irradiation with
two parallel opposed fields to small pelvis at a
dose of 45 Gy in 23-25 fractions and concomitant
chemotherapy with 5-Fluorouracil during first
three and last three days of irradiation.
Main early complications from chemoradiation
included diarrhea (58%), nausea and vomiting
(15%), dysuria (6%), leukopenia (31%) and
anaemia (4%). In total, acute side effects occured
in 42 patients (66%) and in 16 of them (25%)
were of grade 3 or 4. Three patients did
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not complete the treatment due to exacerbation
of side effects and/or serious deterioration of
performance status. Late complications, mainly
from bowels and urinary bladder, occured in 19
patients (30%) and six of then (9%) were
severe.
Nineteen of the 64 evaluated patients have
deceased ill now. Median survival was 29
months (4 to 50 months). Local recurrence was
seen in 14 patients (22%) and distant
metastases - in 18 (28%).
Results of our study show that postoperative
radiochemotherapy in rectal cancer patients is
accompanied by a large number of acute and
late complications. Literature data demonstrate
that better tolerance of treatment may be
achieved with the use of special surgical
techniques preventing the replacement of small
intestines to the pelvis after rectal amputation.
Further improvement may be achieved with the
use of multiple radiation fields, computerized
treatment planning and customized blocking.
Another option is an application of preoperative
radiotherapy - the approach becoming recently
more commonly used.
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